Aid by Sector
Improving access to asthma care for children and adolescents in Uganda
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
MRC ARL award to understand whether innovations like checking every child and adolescent visiting primary care health facilities for asthma symptoms can lead to an increase in the number of children diagnosed with asthma, and whether education about asthma directed to patients and their caregivers can lead to improvements in the understanding of asthma, use of medicines and subsequent reduction in frequency of symptoms.
Unravelling the mechanisms of neurological damage during cryptococcal infection of the brain
DEPARTMENT FOR SCIENCE, INNOVATION AND TECHNOLOGY
MRC ARL award, Cryptococcal meningitis kills more than 200,000 people each year in Sub-Saharan Africa and also causes neurological dysfunction and disability in survivors, most of which are of an economically productive age. Cryptococcal meningitis (CM) is the leading cause of HIV-associated meningitis, which is characterised by debilitating, inflammatory injury of the brain and a very high chance of death, even with treatment. In Sub-Saharan Africa, the number of people who die from CM and its complications is worsened by the unavailability and inaccessibility of safe and effective drugs. This research will fill the existing knowledge gap on how the brain is injured in cryptococcal meningitis. This models and methods would then serve as a platform for studying the mechanisms of other infections of the Central Nervous System that are caused by bacteria, parasites and viruses to inform the development of the much-needed new therapies in South Africa and the wider Sub-Saharan Africa region.
UK Vaccine Network (UKVN) - Engineering and Physical Sciences Research Council (EPSRC) - Future Vaccine Manufacturing Research Hubs Competition 2 (2023-2028)
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. UKVN is collaborating with the Engineering and Physical Sciences Research Council (EPSRC) to run Stage 2 of the Vaccine Manufacturing Research Hubs competition, which funds four hubs (including the two funded in Stage 1). The first stage of the Future Vaccine Manufacturing Research Hubs competition prioritised the development of vaccine products through research into improved vaccine manufacturing. The second stage continues to fund work of the same nature. As in the first competition, the hubs seek to: (1) Develop tools and technologies that allow for easier and quicker manufacturing of vaccines in emergencies; (2) Redesign existing vaccines to make them cheaper and easier to manufacture and easier to deliver in LMIC settings; and (3) Provide bespoke support for researchers developing vaccines for diseases which primarily affect LMICs, so that the vaccines they are developing are as rapid and cost-effective to manufacture as possible. The projects are expected to collaborate with LMIC researchers and industry to support their work. This project was not put out to an open, competitive tender process because, as a non-departmental public body of the UK government, EPSRC is uniquely positioned to manage research calls.
UK Vaccine Network (UKVN) - Medicines and Healthcare products Regulatory Agency (MHRA) - Global Health Security
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. This project is a collaboration between UKVN, DHSC’s Global AMR Innovation Fund (GAMRIF) and the Medicines and Healthcare products Regulatory Agency (MHRA). The UKVN Work Package supports epidemic and pandemic preparedness by expanding the portfolio of research reagents for emerging viruses. Reagents are chemical compounds that trigger chemical reactions and are therefore vital to laboratory research and vaccine development. Simple and timely access to high quality research reagents would accelerate the development of vaccines against emerging infectious diseases, particularly for scientists from LMICs, which are frequently the worst affected. The existing Centre for AIDS Reagents (CFAR) repository at the MHRA has successfully provided a sustained research reagent resource to the scientific community since 1989. Using their existing network and successful operating model, UKVN funding allows CFAR to expand its scope to become the Centre for Infectious Disease Reagents (CIDR) and encourage leading laboratories to deposit state of the art research materials to their repository and produce and commission new reagents. These materials will be prioritised to organisations in LMICs which will benefit from free of charge access. For more information on the GAMRIF work package please see GB-GOV-10-GAMRIF-WP12-MHRA. This project was not put out to an open, competitive tender process because MHRA is an executive agency of DHSC and therefore exempt from the tender process as it is within DHSC’s body of expertise.
UK Vaccine Network (UKVN) - Innovate UK - Vaccine Development for Diseases with Epidemic Potential Competition
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. UKVN is funding Innovate UK to run the Vaccine Development for Diseases with Epidemic Potential competition. The competition aims to support projects seeking to develop vaccines, vaccine platform technologies and manufacturing technologies that will enable an effective, rapid response during future outbreaks of diseases of epidemic potential in LMICs. The projects include work that has progressed from earlier UKVN-Innovate UK competitions, including the Vaccines for Epidemic Diseases: Readiness for Clinical Development and Regulatory Submission Competition, Innovate Vaccine Development Competition 2017-2020, Innovate Preclinical Vaccine Development Competition 2017-2021, and Innovate Clinical Vaccine Development Competition 2018-2021. The successive funding allows for successful previous projects to receive follow on funding and progress vaccine candidates down the developmental pipeline. This project was not put out to an open, competitive tender process because, as a non-departmental public body of the UK government, Innovate UK is uniquely positioned to manage research calls.
UK Vaccine Network (UKVN) - Innovate UK - Vaccines for Epidemic Diseases: Readiness for clinical development and regulatory submission competition
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. UKVN collaborated with Innovate UK to run a Small Business Research Initiative (SBRI) competition to invest in vaccines and vaccine technologies to address the priority disease families identified by UKVN (including Disease X - a pandemic pathogen that has not yet been characterised). Proposals could address any part of the pre-clinical, non-clinical, manufacturing, or clinical pathway, within a one-year time frame, making technology ready to be progressed further along the developmental pathway. The projects built on work from previous Innovate competitions, including: Innovate Clinical Vaccine Development Competition 2018/2021, Innovate Pre-clinical Vaccine Development Competition 2017/2021 and the Innovate Vaccine Development Competition to develop research across vaccine development. This project was not put out to an open, competitive tender process because, as a non-departmental public body of the UK government, Innovate UK is uniquely positioned to manage research calls.
UK Vaccine Network (UKVN) - UK Health Security Agency (UKHSA) - Vaccine Technology Development
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. UKVN funded the UK Health Security Agency (UKHSA) to deliver a programme of seven projects that will advance vaccine development for diseases of epidemic potential for the benefit of people in LMICs. The projects cover a range of pathogens, which have been identified as being a priority area of investment due to lack of current vaccine availability and likelihood of epidemic threat. The projects are primarily focused on enabling activities, such as preclinical model or assay development, to support the development of vaccine candidates for priority pathogens, including through increasing the range of settings where vaccine development and evaluation can take place without a need for higher-containment facilities, which will support future work in LMICs. This project was not put out to an open, competitive tender process because UKHSA is an executive agency of DHSC with a mandate to deliver on pandemic preparedness and therefore exempt from the tender process as it is within DHSC’s body of expertise.
UK Public Health Rapid Support Team (UK-PHRST) - Research
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC). The UK Public Health Rapid Support Team (UK-PHRST) is the primary mechanism for the UK Government to deploy technical expertise in outbreak response to ODA-eligible countries, stopping a public health threat from becoming a broader health emergency. It is a partnership between the UK Health Security Agency (UKHSA, formerly Public Health England (PHE)) and the London School of Hygiene and Tropical Medicine (LSHTM) and was established in 2016 in response to lessons learned from the West Africa Ebola outbreak. The UK-PHRST comprises public health experts who work to address the threat posed by infectious disease outbreaks in low- and middle- income countries (LMICs) through an integrated triple remit of: (1) Outbreak Response: Rapidly investigate and respond to disease outbreaks at source in LMICs to stop a public health threat from becoming a broader health emergency by deploying specialist public health experts; (2) Research: Deliver rigorous, collaborative research with partners to improve the evidence base for best practice in epidemic preparedness and response; and (3) Capacity Strengthening: Strengthen leadership, systems and technical capacity for an improved response to disease outbreaks in ODA-eligible countries.
UK Vaccine Network (UKVN)
UK - Department of Health and Social Care (DHSC)
The UK Vaccine Network (UKVN) is an Official Development Assistance (ODA) funded UKaid programme from the UK Department of Health and Social Care (DHSC). It supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. The long-term aims of this programme are to prevent outbreaks of diseases with epidemic potential through proactive vaccination campaigns or to control them through quick development of new vaccines and/or responsive vaccination campaigns upon outbreak detection. UKVN focuses on human and zoonotic diseases with epidemic potential in humans, from 12 priority pathogen families, alongside Disease X (a pandemic pathogen that has not yet been characterised).
UK Vaccine Network (UKVN) - BactiVac Network - Bacterial Vaccinology Competition
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. The BactiVac Network aims to accelerate the development of vaccines against bacterial infections to reduce antimicrobial use in humans and animals, specifically in LMICs. UKVN funding to BactiVac supports projects that develop vaccines to prevent and/or minimise the emergence and transmission of antimicrobial resistance. A partnership between at least two organisations is a funding requirement, with at least one partner based in the UK, and prioritising partnerships with LMIC researchers. The primary aim of the funding is to encourage the establishment of new, diverse research projects and partnerships which can progress to gain preliminary data and establish their reputation, enabling them to obtain further investment. Funding will also support other UKVN activities which promote collaboration across the membership, particularly for members based in LMICs.
UK Vaccine Network (UKVN) - Coalition for Epidemic Preparedness Innovations (CEPI) - Development of Vaccines Against Diseases with Epidemic Potential
UK - Department of Health and Social Care (DHSC)
This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s UK Vaccine Network (UKVN) which supports the development of vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic in low- and middle-income countries (LMICs), focusing on areas of market failure. UKVN has identified a range of human diseases with epidemic potential in LMICs for which the development of vaccines is a priority. CEPI (the Coalition for Epidemic Preparedness Innovations) is a global public-private partnership established following the 2014-16 West African Ebola epidemic to accelerate development of, and equitable access to, vaccines against emerging infectious diseases of epidemic and pandemic potential. It pools funding from sovereign donors and major philanthropic organisations to: (1) Support the advancement of vaccine candidates for known priority pathogens in LMICs; (2) Advance vaccine platform technology to support accelerated responses to an unknown pathogen (Disease X); and (3) Address key barriers to vaccine access in LMICs, such as distribution of manufacturing capacity.
NIHR Global Health Research Units: Call 2
UK - Department of Health and Social Care (DHSC)
The NIHR's second Global Health Research call for Units. UK universities and research institutes were invited to submit applications, working in equitable partnerships with researchers in low- and middle-income countries (LMIC), to develop their ambitions to deliver world-class applied global health research to address under-funded or under-researched global health areas specific to those countries. Global Health Research Units are defined as a well-established research partnership or network of universities and research institutes in LMICs and the UK: 1. With an existing track-record of delivering internationally recognised applied global health research addressing unmet health needs in ODA-eligible countries; 2. Who wish to consolidate and expand this work, supporting and developing thematic research and capacity strengthening networks, through regional and global hubs; 3. Who will deliver a large scale, ambitious programme of applied health research through a range of trials and studies; 4. Who are able to leverage the strength of the existing partnership consortium to improve practice and inform policy based on scientific evidence; 5. Who will set up and deliver a substantial and sustainable programme of capacity and capability strengthening at individual and institutional level.
NIHR Global Health Policy and Systems Research
UK - Department of Health and Social Care (DHSC)
The UK Department of Health and Social Care (DHSC) funds outstanding global health research through the National Institute for Health and Care Research (NIHR). The NIHR has identified health policy and systems research (HPSR) as a strategic global health research priority. Through a process of stakeholder consultation, NIHR aims to develop a portfolio of activities that will support health policy and systems research for the direct and primary benefit of people in low- and middle-income countries (LMIC).
NIHR Global Health Policy and Systems Research Consortia
UK - Department of Health and Social Care (DHSC)
The UK Department of Health and Social Care (DHSC) funds outstanding global health research through the National Institute for Health and Care Research (NIHR). The NIHR Global Health Policy and Systems Research (Global HPSR) programme funds health policy and systems research that is directly and primarily of benefit to people in low and middle income countries (LMICs), and to improve access to appropriate and affordable health services aligned with the aims of Universal Health Coverage and Sustainable Development Goal 3. The Global HPSR Consortia call supports broad ambitious programmes of health policy and systems research and capacity strengthening delivered through a consortium of partners. UK and LMIC universities and research institutes were invited to submit applications including two joint lead applicants, at least one of whom must be employed by a LMIC institution.
NIHR Global Health Policy and Systems Research Projects: Call 1
UK - Department of Health and Social Care (DHSC)
The UK Department of Health and Social Care (DHSC) funds outstanding global health research through the National Institute for Health and Care Research (NIHR). The NIHR Global Health Policy and Systems Research (Global HPSR) programme funds health policy and systems research that is directly and primarily of benefit to people in low- and middle-income countries (LMICs), to improve access to appropriate and affordable health services aligned with the aims of Universal Health Coverage and Sustainable Development Goal 3. Global HPSR Projects Call 1 supports applied health policy and systems research projects. UK and LMIC universities and research institutes were invited to submit applications including either a sole LMIC Lead Applicant, or two Joint Lead Applicants from either a LMIC or the UK, at least one of whom must be employed by a LMIC institution.
NIHR Research and Innovation for Global Health Transformation: Call 1
UK - Department of Health and Social Care (DHSC)
National Institute for Health and Care Research (NIHR)’s first Research and Innovation for Global Health Transformation (RIGHT) call. RIGHT funds cutting-edge interdisciplinary applied health research in key areas in in low- and middle-income countries (LMICs) where a strategic and targeted investment can result in a transformative impact. RIGHT Call 1 addresses research in three key areas: epilepsy, infection-related cancers and severe stigmatising skin diseases. UK universities and research institutes were invited to submit applications including a co-applicant or joint lead applicant from an LMIC relevant to the research proposal. Research must be focused on improving the health and welfare of people in LMICs.
NIHR Research and Innovation for Global Health Transformation: Call 3
UK - Department of Health and Social Care (DHSC)
National Institute for Health and Care Research (NIHR)'s third Research and Innovation for Global Health Transformation (RIGHT) call. RIGHT funds cutting-edge interdisciplinary applied health research in key areas in low- and middle-income countries (LMICs) where a strategic and targeted investment can result in a transformative impact. RIGHT Call 3 supports equitable partnerships between LMIC and UK researchers to generate new research knowledge and evidence on interventions to improve outcomes for those affected by multimorbidity in ODA-eligible countries. UK universities and research institutes were invited to submit applications including a co-applicant or joint lead applicant from an LMIC relevant to the research proposal. Research must be focused on improving the health and welfare of people in LMICs.
NIHR Research and Innovation for Global Health Transformation: Call 4
UK - Department of Health and Social Care (DHSC)
National Institute for Health and Care Research (NIHR)'s fourth Research and Innovation for Global Health Transformation (RIGHT) call. RIGHT funds cutting-edge interdisciplinary applied health research in key areas in low- and middle-income countries (LMICs) where a strategic and targeted investment can result in a transformative impact. RIGHT Call 4 supports equitable partnerships between LMIC and UK researchers to generate new research knowledge and evidence to address the global burden of unintentional injuries (including but not limited to road traffic accidents, falls, burns and drowning, and urgent and emergency care). UK and LMIC-based universities and research institutes were invited to submit applications. Research must be focused on improving the health and welfare of people in LMICs.
NIHR Research and Innovation for Global Health Transformation: Call 5
UK - Department of Health and Social Care (DHSC)
National Institute for Health and Care Research (NIHR)'s fifth Research and Innovation for Global Health Transformation (RIGHT) call. RIGHT funds cutting-edge interdisciplinary applied health research in key areas in low- and middle-income countries (LMICs) where a strategic and targeted investment can result in a transformative impact. RIGHT Call 5 supports equitable partnerships between researchers to generate new research knowledge and evidence on interventions aimed to strengthen health service delivery and resilience for extreme weather events in ODA-eligible countries. UK and LMIC-based universities and research institutes were invited to submit applications. Research must be focused on improving the health and welfare of people in LMICs.
NIHR-Wellcome Global Health Research Partnership
UK - Department of Health and Social Care (DHSC)
This partnership between the UK’s National Institute for Health and Care Research (NIHR) and Wellcome funds global health researchers who focus on health priorities in low- and middle-income countries.
Advanced filters
To search for Programmes in a specific time period, please enter the start and end dates.